Dermapharm Holding SE successfully maintains growth trend as planned

Grünwald, 16 November 2022 – Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals, today publishes its results for the first nine months of 2022.

Grünwald, 23 August 2022 – Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals, today published its unaudited preliminary IFRS consolidated financial results for the first half of 2022. During the first six months of the financial year 2022, Dermapharm increased revenue by 10% to EUR 471 million (same period of the previous year: EUR 428 million). At the same time, adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) increased by 9% to EUR 149 million (same period of the previous year: EUR 137 million).

Grünwald, 7 September 2022 - Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of off-patent pharmaceuticals for selected therapeutic areas in Germany, today published its report on the first half of 2022. Dermapharm also confirmed its preliminary consolidated figures (IFRS).